Tabula Eur Ultras Ig Bond Paris-aligned Ucits Etf (TUCP) News

Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance

Boston (June 27, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2...

Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer

Multiple patients have now exceeded 30 weeks on treatment Boston (June 25, 2024)—Allarity Therapeutics, Inc...

Form 8-K - Current report

Form 8-K/A - Current report: [Amend]

Form 8-K - Current report

Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

Boston (May 20, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances

- Phase 2 Trial of Stenoparib Concluded Early due to Clear Clinical Benefits Achieved - On Track to Regain...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

Form RW - Registration Withdrawal Request

Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock

- Conversions Eliminate All Variable Priced Derivative Securities - Conversions Eliminate Any Market Overhang...

Form 8-K - Current report